Tandem Diabetes Care (TNDM) Expected to Release Quarterly Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.34) per share and revenue of $254.99 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.16. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The business had revenue of $247.22 million for the quarter, compared to analyst estimates of $240.41 million. During the same quarter in the previous year, the company posted ($0.66) earnings per share. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. On average, analysts expect Tandem Diabetes Care to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Tandem Diabetes Care Stock Performance

Shares of Tandem Diabetes Care stock traded up $0.50 during trading hours on Tuesday, hitting $20.61. 260,494 shares of the company were exchanged, compared to its average volume of 2,109,744. The company has a current ratio of 3.58, a quick ratio of 3.07 and a debt-to-equity ratio of 4.54. The business has a 50-day moving average of $16.62 and a 200-day moving average of $18.89. Tandem Diabetes Care has a 1 year low of $9.98 and a 1 year high of $29.65. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -14.73 and a beta of 1.53.

Institutional Trading of Tandem Diabetes Care

Several large investors have recently modified their holdings of the business. Freestone Grove Partners LP purchased a new position in shares of Tandem Diabetes Care during the third quarter valued at approximately $22,706,000. First Light Asset Management LLC purchased a new position in Tandem Diabetes Care during the fourth quarter worth about $23,947,000. Marshall Wace LLP purchased a new position in Tandem Diabetes Care during the fourth quarter worth about $19,244,000. Balyasny Asset Management L.P. acquired a new stake in Tandem Diabetes Care in the 4th quarter worth about $5,776,000. Finally, Goldman Sachs Group Inc. boosted its stake in Tandem Diabetes Care by 17.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,683,400 shares of the medical device company’s stock worth $37,001,000 after buying an additional 252,028 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. TD Cowen restated a “buy” rating and set a $28.00 price objective (up from $25.00) on shares of Tandem Diabetes Care in a research report on Monday, April 20th. Benchmark assumed coverage on shares of Tandem Diabetes Care in a report on Monday, May 11th. They issued a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Tandem Diabetes Care in a research note on Tuesday, June 23rd. They set a “hold” rating and a $15.50 price target on the stock. Truist Financial restated a “buy” rating and issued a $31.00 price objective (down from $35.00) on shares of Tandem Diabetes Care in a research report on Monday, May 11th. Finally, UBS Group assumed coverage on Tandem Diabetes Care in a research report on Tuesday, July 28th. They set a “neutral” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.73.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.